Good day, and thank you for standing by. Welcome to Axonics' Q1 2021 Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one on your telephone. If you require any further assistance, please press star zero. I would now like to hand the conference over to your speaker today, Neil Bhalodkar, investor relations. Please go ahead. Thank you, Peter. Good afternoon, and thank you for joining Axonics' quarterly results and update call. Presenting on today's call are Raymond Cohen, Chief Executive Officer, and Dan Dearen, President and CFO. Ray and Dan will provide prepared remarks on first quarter financial results, commercial progress, and a general business update, followed by a Q&A session. Before we begin, I would like to remind listeners that statements made on this conference call that relate to future plans, events, prospects, or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While these forward-looking statements are based on management's current expectations and beliefs, these statements are subject to a number of risks, uncertainties, assumptions, and other factors that could result to differ materially from the expectations expressed on this conference call. These risks and uncertainties are disclosed in more detail in Axonics' filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date, May 6th, 2021. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, circumstances, or unanticipated events that may arise. I'd now like to turn the call over to Ray for his remarks. Thank you, Neil. I'd like to welcome everyone joining the conference call this afternoon, and for folks who may be dialing in for the playback. I'm pleased to report that Axonics generated $34.4 million of revenue in the first quarter of 2021, which represents an increase of 31% compared to the same period of 2020. We're proud of this result considering the strong headwinds in January and February, which disproportionately affected elective procedures, as well as the normal seasonal impact of patients not having yet met their insurance deductibles. The good news is that in the U.S., we saw a solid rebound in sales in March that has continued into April and early May. By contrast, much of Europe continues to remain in lockdown. We're confident, however, that as more people are vaccinated and we return to a more normalized elective procedure environment in the months ahead, that Axonics is poised to continue to grow revenue meaningfully in 2021 and beyond. There is no doubt that the U.S. Sacral neuromodulation market is growing, and this will become much easier to measure once the pandemic recedes. The opportunity for Axonics is significant considering how vastly under-penetrated the market is for treating any form of incontinence. Sacral neuromodulation is poised to expand into a multi-billion dollar annual market in the United States based on the fact that tens of millions of women are suffering from these conditions. Response to our recent acquisition of Bulkamid has been overwhelmingly positive as anticipated. The expanded offering has elevated Axonics' stature with the urology and urogynecology community. Bulkamid is a strong strategic fit for Axonics, given that our commercial team is already calling on these customers. Clinicians are enthusiastic to offer this safe and efficacious next-generation bulking agent to women suffering from stress urinary incontinence. We see Bulkamid as providing us with an opportunity to sell more sacral neuromodulation, in particular to those accounts in the U.S. that have not yet converted their sacral neuromodulation business to Axonics. Physicians working with Axonics now have a complete set of tools to treat patients presenting with stress urinary incontinence, urge urinary incontinence, mixed incontinence, urge urinary frequency, urinary retention, as well as bowel incontinence. Integration and training for Bulkamid is ongoing and is anticipated to be completed during this quarter, at which point we'll be able to fully leverage our 250-person commercial team and roll out Bulkamid more broadly in the U.S. Internationally, we're also working to get Bulkamid sales representatives trained on sacral neuromodulation and for the Axonics SNM team to be trained on Bulkamid. Our commercial success continues to be grounded in providing our customers with exceptional support while simultaneously or significantly, I should say, improving the quality of life for their patients. We continue to hear from clinicians that more of their patients are saying yes to sacral neuromodulation therapy than ever before, and that they're excited to incorporate Bulkamid into their practices. As we speak, the overall market for SNM is expanding, driven by technological advances, strong clinical outcomes, and increased patient awareness. We believe that Axonics will continue to be cause in the matter of driving durable sacral neuromodulation market growth in the years ahead. For the first time in our history as a public company, we're instituting full year revenue guidance. To that end, for the full year of 2021, we anticipate revenue to fall between $176 million and $180 million, which represents an approximate 60% increase compared to revenue of $111.5 million in 2020. We expect slightly more than 90% of that revenue to be attributable to sacral neuromodulation sales and the balance to Bulkamid. Changing topics on the subject of clinical and regulatory, we continue to enhance the patient experience and build a strong body of clinical evidence for Axonics sacral neuromodulation therapy. A few notable items from the past quarter include that in January of 2021, a manuscript discussing the two-year outcomes of our ARTISAN-SNM pivotal study were published in Neurourology and Urodynamics, the official journal of the International Continence Society. The two-year responder rates in the ARTISAN-SNM pivotal study represent the highest ever reported in this body of clinical literature. The clinically significant and durable symptom relief and high degree of patient satisfaction reported by study participants is being replicated every day by our customers around the world. In February, the FDA approved Axonics' third-generation implantable neurostimulator. As a reminder, the third-generation neurostimulator has upgraded embedded software, which enhances the functionality of the device system and the patient remote control. These modifications give patients the ability to make broader stimulation parameter adjustments at home, including selecting a second therapy program that was set post-operatively based on intraoperative findings. Now, we began shipping the third-generation implantable neurostimulator in the first week of March, and the feedback from both physicians and patients has been overwhelmingly positive. We also have a registry study called ARTISTRY, and that study is now enrolling and implanting patients at a nice clip. We have over 50 patients already enrolled in the registry towards our goal of approximately 300. On the product development front, we continue to make strong progress on our non-rechargeable or primary cell neurostimulator. We are working diligently and expect to file with the FDA before the end of June, and are optimistic that we can have the product approved and in the market in the U.S. in the first part of 2022. With that said, I'll turn the call over to Dan, who will review our first quarter 2021 financial results. Dan? Thank you, Ray. For the first quarter of 2021, Axonics generated net revenue of $34.4 million. This represents an increase of 31% compared to $26.3 million in the prior year period. Sacral neuromodulation revenue was $32.9 million, of which $31.7 million was generated in the U.S., and the remainder in select international markets. Bulkamid revenue for March was $1.5 million, of which $578,000 was generated in the U.S., and the remainder overseas. The Bulkamid contribution this quarter was for only one month and one day as the acquisition closed on February 25th of this year. Overall, total net revenue from the U.S. accounted for $32.3 million, with certain international markets contributing $2.1 million of revenue. Gross profit for the first quarter of 2021 was $20.4 million, representing a gross margin of 59.3% compared to 62.4% for the three months ended March 31st, 2020. The decrease in gross margin for the quarter is due to lower absorption and manufacturing variances, which included a lower yield rate than anticipated as we continue to work with our contract manufacturers to increase our manufacturing output. While we expect to see some variability in gross margin quarter-to-quarter, we fully anticipate gross margins will increase during 2021 and land in the low to mid-70s% in the next few years. Total operating expenses for the first quarter of 2021 were $42 million. Included in this figure is $4.4 million of one-time legal consulting and advisory expenses related to the Bulkamid acquisition. Also included in operating expenses is $700,000 of amortization of intangibles expense related to the acquisition. Adjusting for these items, operating expenses were approximately $36.9 million, in line with our budget and reflective of increased headcount compared to the prior year period. In the year-ago period, operating expenses totaled $31.1 million. We expect operating expenses in Q2 to be in the range of $43 million-$45 million. This increase is mainly due to the additional operating costs for Bulkamid. This estimate includes approximately $3 million in incremental operating expenses and $2 million in amortization expense on the acquired intangible assets. Net loss for the first quarter of 2021 was $22.5 million, compared to a net loss of $14.6 million in the prior year period. Cash and cash equivalents were $131 million as of March 31st, 2021. I will now turn the call back over to Ray for additional remarks. Thank you, Dan. I'd like to add some color on a number of items. First, as of April 25th, we now have over 503 employees at Axonics. This is more than double since this time in 2020. The number of employees engaged in field activities is about half of our total headcount. In the U.S., we have a total of 107 salespeople and sales managers. We have nearly 110 clinical and therapy support specialists, a handful of field marketing specialists, and a clinical education group, which represents five professionals, and they are led by our Chief Medical Officer and one of the world's foremost experts in urogynecology, Dr. Karen Noblett. In Europe, between Bulkamid salespeople and sacral neuromodulation salespeople and clinical specialists, we have 27 individuals. I think this is an important comment to make, considering the variation in the growth market for the first quarter, and that is, our average selling prices over the past three quarters have been stable. The mix of where purchase orders are coming from, or originating from, has shifted. All procedures are performed in outpatient settings, either in the hospital or in ASC, now nearly two-thirds of our purchase orders come from hospital systems. This is resulting from the fact that we have signed agreements to supply our sacral nerve modulation system to over 200 national and regional IDNs and local facilities, and we've accomplished this over the past year. As stated in the past, these agreements are mainly hunting licenses with certain volume targets. We are now adding Bulkamid as an addendum to many of these agreements. I know there's been some interest in hearing more about our marketing efforts and particularly direct-to-consumer advertising. During Q1, we invested approximately $1 million in a combination of activities, including Facebook ads, paid internet search, and search engine optimization. In addition, we worked with our customers to support mailings from physicians to their own patients, some local print advertising, and some short TV spots. Suffice it to say, we've reached tens of thousands of potential patients. We've generated hundreds of leads and appointments in physician offices and are now seeing this interest turning into procedures. Our messaging will now include offering solutions for all types of incontinence, regardless of whether it's stress or urge incontinence. We believe this will also increase our response rates, lower cost per lead, and drive even more patients into the practices of the physicians who are loyal to Axonics. We are now live in 42 markets in the U.S., up fourfold from December 2020. We will continue to expand into more markets and invest a reasonable amount of additional capital into these efforts throughout 2021. In closing, with respect to prepared remarks, we're incredibly bullish about the outlook for our sacral neuromodulation portfolio and Bulkamid over the next several years. We're grateful for the trust that physicians, patients, and shareholders have placed in Axonics. I can assure you we continue to work diligently every day to fulfill our mission of changing the lives of patients suffering from bladder and bowel dysfunction and being the market leader for sacral neuromodulation. At this time, we're happy to take some questions. We'll turn it to the operator. Thank you. As a reminder, to ask a question, you will need to press star one on your telephone. Please stand by while we compile the Q&A roster. Your first question comes from the line of Bob Hopkins with Bank of America. Oh, great, and good afternoon, and congrats on a strong quarter. Thank you, Bob. Appreciate the detail. Let me just a couple clarifying questions. It looks like you're guiding to about $18 million of Bulkamid sales for the year and about $160 million on the sacral neuromodulation side. First of all, is that correct? No. Okay. It's not. I think you're about $4 million higher on the Bulkamid based on your comment. That should be put into the sacral neuromodulation side of the ledger. Oh, okay. You're only guiding to $14 million. That would imply that you have no improvement in monthly run rate from here on Bulkamid. Right. Or? Yeah, let me just make a comment about that, Bob. I appreciate that question and a chance to clarify. Look, we clearly overachieved in the month of March. I don't think any of us expected to generate nearly $1.5 million of revenue in March. Now, in Q2, things are going to not be at such a great clip, right? In other words, if you took March, times it by three, you'd say, "Wow, you guys should do $4.5 million." Here's the difference. We had a nice, strong result in the United States in March. However, those individuals that were involved in selling that product are the ones that are training our 110 clinical specialists and the salespeople and all that, and that's happening in Q2. We're a little bit shy really about even the analyst consensus of $3.4 million in Bulkamid, and we're a little more comfortable around $3 million just because we're diverting resources, selling resources to do training. Also just to underscore the point, our own sacral neuromodulation sales force is not out selling Bulkamid at this time. We are still in the mode of training people and getting up to speed. They will start to contribute in Q3 of 2021. The increase, if you may, over and above consensus, is from sacral neuromodulation. Bob, as you saw from the numbers, we overachieved in that category in Q1, and we're saying, "Okay, fine, let's take that number, put it into the overall consensus number," and then we're suggesting that we could be higher by some millions beyond that. Hopefully this kind of clears up the story. Yeah, it does. Just one follow-up on the Bulkamid side then. Just obviously, is that sort of what you saw in April and early May in terms of more like a $1 million monthly run rate versus the $1.5 million in March? Yeah, just because, as I mentioned, we've diverted resources. We've trained nearly 60 people already just in these weeks, in April and May. Obviously, our people can't be in two places at one time, right? They're good, they're not that good. That's kind of the situation. Look, we're optimistic. The other issue, just to put a finer point on it even further, Germany is under lockdown until the middle of June. That's almost all of the quarter, not really seeing any action with everybody still hiding under their desks, in Germany. The U.K. is not in much better shape, as you have seen from the historical numbers, the number was much bigger internationally than it was in the U.S., which is the market that's just coming around. That's the issue, right? We've got U.S. people involved in training. We got the international markets, most of them still having problems from COVID. We'll do fine. I think it'll be respectable. We're just trying to provide some color so that people really can have a better sense about what to expect from the company in the short term. When does that sacral neuromodulation sales force really go out and market Bulkamid? When does that happen? It won't happen until well into the third quarter, right? Okay. It's one thing to get sacral neuromodulation salespeople and clinical specialists who are engaged in a highly technical product and implants. It's one thing to get them up and running on Bulkamid. It's a little more of a heavy lift to go the other direction. It'll all come together, and we'll see some benefit from the synergy as we go forward. I will add just one more comment since it sounds like I'm talking down Bulkamid, and we're really not because the demand for this product right now is significantly higher than our ability to actually get to these customers. Okay. That's helpful. One quick last one in terms of just the core sacral neuromodulation business. Given it's such a unique quarter, just wondering if we could get any rough sense for how March was and whether or not April was better. Thanks, Bob. March was a really good, solid month. I think you've heard this refrain from all the other companies that have reported. April continued even though it was the first month of the new quarter. It continued at that good pace and into the first days here of March, things are looking pretty good. This is why we're being more bullish, even in the short run, and are suggesting that we could even see an increase over analyst consensus for Q2 in the short run. Things are good, and it's just great to see more people getting vaccinated, elective procedures opening up, and so forth. Things are definitely getting better and we're seeing incremental improvements literally month to month now. Excellent. Thanks for taking the questions. Thanks, Bob. Your next question will come from Chris Pasquale with Guggenheim. Thanks. Congrats on the quarter, guys. Ray, I'm just curious whether you saw scheduled procedures canceled in the early part of the quarter that you then were not able to make up in March? Would love to get a sense for whether there's a new group of sort of pent-up demand patients that could come back in here over the next couple of months? Chris, look, there were some cancellations, particularly like in the January period. They're nowhere near as much of a problem as what we saw in Q4, right? Where we actually went out there, did a survey, put a number to it. I think it was 320-odd procedures that were canceled in Q4. We just did not see anything near that in Q1. Really, there's not much for us to say about it. I think the numbers that we generated in Q1, I think they speak for themselves. It was a good quarter for us, and we're obviously seeing incremental increases and optimistic about uptake of the product as we continue. That's helpful. I appreciate the comments around the DTC campaign and the work you're doing with customers. $1 million is not insignificant, but it feels as though the market is sort of taking off in advance of some of the investments that you guys have really talked about from a market development standpoint. Are you feeling that? How has your experience over the past call it nine months or so colored your view on what's going to be necessary to get to that multi-billion dollar level of adoption that you spoke about in your script? It's a good question, Chris. I think that this is happening also on a very much of an organic basis. Right? We continue to say, we've said this line many times, patients are saying yes to the therapy more often than ever before. That's what docs are telling us, that's what our customers are telling us. There is a groundswell of interest that is happening organically. The fact that there are letters going out to patients from practices suggesting that they may want to come back in and talk about new technology, the fact that we're on Facebook and that there's a lot more action out there and more awareness, even our competitors starting to do a little something in this particular area, which we applaud. Rising tide is going to help all players in the marketplace. It's happening. Look, I'm not a subscriber to Harper's Bazaar, when you hear that the pelvic floor is getting a PR makeover, there's a lot of interest now starting out there in, how should we say, in the world and particularly in the United States, about this particular topic. I think you're going to see that this is going to happen both from an organic standpoint, just increased awareness, people talking to each other. There's just a lot more action going on. Here's the bottom line. When it comes to sacral neuromodulation, this is really more about physicians being more comfortable with talking about the therapy because we've got a better product, and it's long-lived, and it's MRI compatible, and it's easy to use, and you're going to get a great clinical result. This is the big difference. This is no longer a therapy of last resort, which is what it was before we entered the market. I think what we're trying to do is just put some more gas on the fire, so to speak, and keep things moving in the right direction. I don't mean to be talking down DTC. We got tens of thousands of people who raised their hand and said they're interested, but it's a long-term process to convert that initial interest into actually somebody showing up for a procedure. Right. It's a multi-year effort. If I just look at Inspire Medical, I think they disclose this and hopefully I'm reporting something everybody know, but they spent $27 million on DTC in 2020. We applaud that. We think that's great. We're not quite there yet. We're not the only player in the marketplace either. It takes time, and there will need to be continued investments over time. We're trying to do this in a smart way, Chris, and kind of do the blocking and tackling before we get over our skis. I think you're hearing a little bit of conservatism from us. We will continue to invest additional money in DTC, but we want to try to keep it in kind of a rational vein and really focus on how we're processing those leads, how they're landing in physicians' offices, how they're being followed up. We're really heavily engaged in kind of process of how these things really work because we're operators, and that's just kind of our background, and we want to make sure that we're getting a return on investment. Makes sense. Thanks. Thank you, Chris. Your next question will come from Kaila Krum with Truist Securities. Hi, guys. Thanks for taking our questions and all the detail on the guidance. Just one of the things I'm curious about is how you're assuming Bulkamid can have a halo effect on the SNM business. A lot of patients have both SUI and OAB. I guess, are there SNM patients who actually have an Axonics implant today that could benefit from a Bulkamid injection? Just curious how you're thinking about sort of the synergies between the two businesses. Yeah. Thanks, Kaila. You're correct. I'll take the technical part of the question first. You are correct that there are a group, maybe as much as 20% of patients who we call mixed incontinence patients. These are patients that have a form of stress urinary incontinence and urge urinary incontinence. Many times the docs try to do a differential diagnosis, maybe using different techniques and urodynamic testing and things of that nature to make that differentiation. Really, it's about which is the greater bother for the patient. We all know that if you've got urge urinary incontinence, that's a lot more bothersome than coughing, sneezing, lifting an object, and leaking a little bit of urine. There's no question that existing patients who may already have a sacral neuromodulation device in their body, or may be in the process of getting worked up for that could also benefit from bulking injections, Bulkamid in their urethra. That's the technical part. There is this crossover of these patients. They're not completely unique from one another. The bigger question that you're asking really gets to why did we buy Bulkamid? Okay. Yeah, we're excited about the product. It's cool, it's great, and we think we can do $50 million by 2024. The main reason really is that we believe that Bulkamid is helping us right now in real-time and will continue to help us sell more sacral neuromodulation because we're able to get into accounts with Bulkamid that they've been in the Medtronic camp in terms of sacral neuromodulation business. We're getting in there, working with those accounts, letting them see who Axonics is, how we go about doing our business, being professional and all the other things that we do, engenders confidence in that account, in that customer, in that physician, in their staff, and puts us in a position for them to give us a shot so that we can prove to them that, in fact, we've got a better product, and superior service, and so on and so forth, on the sacral neuromodulation side. I will tell you, Kaila, it is happening. It's happening in real time, and the fact of the matter is, we've got accounts that we've not been able to sell sacral neuromodulation to that have invited us in because of Bulkamid, and they are now open, and some of them have already started working with us on sacral neuromodulation. The theory or the hypothesis behind doing the acquisition is playing out in real time, and is happening very quickly. We're really thrilled about that. That's going to help also fuel the growth of our sacral neuromodulation business, not only in 2021, but beyond. Great. Okay. We've heard from a surgeon who does a lot of, or at least historically did a lot of slings. He thinks the market could go to 80% of bulking within the SUI market. Largely, again, because of Bulkamid. What's your reaction to that estimate? Your view there, as I'm sure, again, you've had a lot more conversations with customers than we've been able to. Thank you, guys. Yeah. Thanks. Yeah, no doubt about it. It's interesting. I'm going to quote a study that was done actually in England. It was under the banner of what women want, and it was with respect to not other things, but what they want in terms of treating their stress urinary incontinence. 67% of the respondents, and this was hundreds, not just a dozen people, right? These were hundreds of people who responded that Bulkamid is what they would prefer as a treatment as compared to an operation for sling. That was a pretty impressive number, right? When you go out, you give some basic information, and people responded in that way. We may never get to 80%, but the point is, it's going to be better than 50% and may be approaching this kind of number. The fact is people would prefer to have an injection in their urethra with a material that doesn't have adverse events, that is going to last for five to seven years. That can be done in the office. That's a less than 15-minute procedure. Given the choice, why would you choose an operation? There may be other reasons, and there may be some patients that are more suitable for a sling based on the severity of their condition. Bulkamid is never going to be exactly as efficacious as a sling. You're talking about something is going to give you 70% relief in terms of your symptoms as opposed to 90%, but turns out to be a 10 or 15-minute procedure in a doctor's office as opposed to an operation with recovery time. It's pretty clear what the preferences of these patients are. Now the key thing is to get the docs that are out there to talk to their patients, to give them the option, explain the benefits, and I don't think there's any question that we are going to see a sea change here in how stress urinary incontinence is treated in America. We already have seen it happen in the U.K. as an example, right? In the U.K., this is the standard of care for patients with SUI. Thank you, guys. Thank you. Your next question will come from Larry Biegelsen with Wells Fargo. Hey, Larry. Hi. It's actually calling in for Larry. Thanks for taking my question. No problem. I want to start with a comment you made about there was some backlog in Q4. There were some cancellations. Did that backlog get resolved this quarter? Was there a little bit of benefit from that? It's one of these things where we have not spent a lot of organizational energy in tracking these patients by name. I can't really answer that question in any kind of definitive terms. Clearly, some of these patients came back. I would say a fair number of them have not come back yet. If you think about where we are in terms of vaccination in America, we're at what, maybe 40% of the population. Clearly, a lot of those patients that canceled had not been vaccinated and are still not vaccinated to this moment. I cannot say that, oh, the increase in Q1 was a big pickup over cancellations from Q4. Got it. Okay. It sounds like maybe there is still some pent-up demand, whether it's from Q4 or early part of Q1, just based on procedures getting canceled and may not be fully rescheduled. Yeah, I think that's a correct statement, and I think it really boils down to the environment, right? Elective procedures are starting to come back. Institutions are willing to allocate more time and resources, and so on and so forth. I think it's not one thing. It's a combination of many factors. I do believe that what you're going to see, and I've said this before, is that if you draw a line and you trace the% of people that are being vaccinated in the U.S., you'll see that the Axonics revenue will follow that trend line. Got it. Okay. That's helpful. Just another question around revenue. You mentioned that your SNM reps are getting trained on the new product. Would that have some sort of effect on the revenue cadence in Q2 versus second half of the year, just in terms of these reps being off the field for training? To put a finer point on it, we're training our clinical specialists first. These are the people that are going to be doing wet lab training and are going to be there to support the initial injections in patients. This is more about our clinical specialist staff, not so much our salespeople. We are not taking time out of salespeople's schedule to have them become experts on how to do injections. That's not their job, right? They can talk about the benefit of the product and how it can help people with practices and all the rest of it, but we're not getting our salespeople bogged down in becoming experts on how to inject this material, because they're not going to be the ones that are going to be there to support these cases. With respect to clinical specialists, these are the folks that are focused on case coverage, and we have the ability, obviously, to manipulate these calendars and to keep the wheels on the bus as we're taking these people out of the field for two days or three days at a time. You will not hear this as an excuse from us, that, "Oh, gee, we had to train people and therefore we didn't make our numbers." You will not hear that excuse from us. Got it. Okay, just last question. On your primary cell device, you plan to file that before the end of June. Can you just talk a bit about the potential advantages over the competition, like InterStim II? Thanks again for taking the question. Thank you. I really appreciate that question, and I would be happy to speak in more detail about it, because I think that this is really important and this is a huge value driver for Axonics. Here are the facts. The device is approximately 11 cc's, which is about twice the size of our existing implanted neurostimulator. That's about a little over 20% smaller than the InterStim II. Its profile is different. It's much thinner than the InterStim II. All these things will accrue to our benefit in terms of placing this device in the body. The device will last for a nominal setting, meaning the average patient will get 10 years or more out of this device. This is a watershed, completely different story compared to what is available from the competition, where despite what they might say, there are dozens of clinical studies which suggest that that device will last about four years. Some people aren't so lucky. It only lasts for two or three years in their body. The key thing is longevity in the body. Size is going to be attractive. A couple other key points. This uses constant current technology. That's the same technology we use in our existing rechargeable device. We expect excellent efficacy with this device, no change from that standpoint. It uses the same lead technology, right? We have the same lead that goes with either device. I think the most important thing here is now we're going to have physicians that will be able to direct their patients or give them choice as to which way they would like to go. Think about the lineup. You got a non-rechargeable device that could last 10 years in the body. It'll be the first recharge-free system in sacral neuromodulation. What do I mean by that? You don't have to recharge the stimulator, and our patient remote doesn't have replacement batteries, doesn't need to get plugged in the wall. You don't need to stand on your head to make it connect to the implanted stimulator. We got a recharge-free system that's going to be long-lived, that's going to generate high levels of efficacy based on the constant current technology. It's got a nice footprint in terms of the size and the shape. That's the specs, and those are the key things that matter. I dare say that we are very anxious to get this product in the market, because we think this is going to be a big runner and is going to put a lot of pressure on the incumbents' franchise. Thanks for that question. Your next question is from Michael Polark with Baird. Hey, good evening. I guess the veil has been lifted on the primary cell, thanks for that, Ray. The question I had is, I think at the last disclosure, you had 600 centers signed up for SNM. Mentioned in the prepared remark that obviously Bulkamid is an opportunity to call on folks that aren't using Axonics. I think, back last year or the year before, it was give or take 1,000 centers explain 80% of the SNM volume historically. Curious, not going to hold your feet to the fire on this, but what are your latest and greatest internal expectations for how many of these centers may take your call and start engaging with Axonics and SNM as a result of Bulkamid over the course of the next year or two? Yeah. Michael, thank you for the question. That's a really hard question for me to answer. I'll tell you what our philosophy is and the things that I tell our own people. We want all the business. We want them all. We're not going to rest until we get our fair share of the market, which we define as at least 51%. We're at it every day, and it's hard to make a prediction in any kind of precise terms. I'm not trying to be evasive. Yep. It's a really difficult question to answer. We're on it, and the hypothesis is working, and clearly, we're going to look to bring as many of those important accounts to Axonics as we can and as fast as we can. That's the game that we're playing. Fair enough. A follow-up easier one perhaps for Dan. Appreciate the carve-out of the intangible amort and deal-related expenses in 1Q. The $4.4 million of deal-related expenses in 1Q, heard that. Is there anything like that you expect in 2Q, or is 2Q really your core OpEx number plus the deal-related amort? That's correct. We're not expecting anything in the order of magnitude of, obviously, $4.4 million in one-time expenses for not planning on doing another Contura acquisition. If you assume the current operating expense run rate for Q2 prior to Bulkamid and put that at $38 million-$39 million, and then if you add the incremental expense associated with the Bulkamid OpEx, we expect to see those expenses, excluding amortization, of approximately $42 million. And then amortization of the intangibles is going to run at about $2 million per quarter going forward. Got it. Thank you. Thanks, Mike. Thank you. Next question is from Mike Matson with Needham & Company. Hi. Just want to clarify a few of the comments you guys made during Dan's portion. I think it was Dan's, maybe not. The ASPs, I think you said they were stable, but the mix changed. I guess I was confused by what that means. Does that mean that? Okay if you look at the average price of everything you sold, it was unchanged, or within particular categories it was unchanged, but the mix shifted, and that caused the overall ASP to change? Okay. Thank you for making us clarify that remark, and maybe I combined two thoughts together in the same sentence without a period. Okay. Sure. I apologize for that. Let me clarify. Our average selling prices are stable, and they have been stable over the last three quarters. In other words, literally, it's been a couple of dollars difference quarter- to- quarter. They're 100% stable. I thought that was an important comment for me to make, Mike, because I didn't want people to think, given that we had this hiccup on the gross margin, which is really not a big deal. It's something, when you're early in the cycle, the way we are as a company, you're going to see some variability from quarter-to-quarter, depending on how much product you make or don't make and things that way. The prices are stable. No sliding of our average sale price. Period. Okay. What I did say is that the purchase orders that we get as a company, now two-thirds of those purchase orders are coming out of hospital systems, as opposed to the last time I talked about it, I said it was kind of a split, half and half if you may, between hospitals and ASCs. Given the number of big national IDNs and regional IDNs that we've signed up, we're just getting more business now, purchase orders coming from those institutions. Right? Those were the two messages I was trying to get across. Okay, thanks. That's helpful. I want to ask about Bulkamid now that you've got it in your own hands and you're out there selling it. What kind of reorders are you seeing? Part of the premise here was that the customers, once they kind of get trained and start using it, they'll continue to use it on your own. You won't need to have your reps there for every case. Is that actually playing out that way? 100%, Mike. 100%. Once they get trained, we don't need to be there. The idea is you do a wet lab, you get them up and running, get to practice. You get some patients that are either that day or the next morning. You support them with those first three, four, five, six patients, whatever it might be. Then they're on their own, then you're just going to pop in as you normally would do as a company to make sure your customers are happy and things are going well. We don't need to be there, that's great because that helps us a lot. It's a light touch from that standpoint. What I will say is that, given that we have not unleashed our own sales force on the market, we have seen a nice brisk pace of reorders. We are seeing physicians becoming evangelists about this product. This is really amazing and well beyond our own expectations that the physicians that got trained in 2020 on this product, they are making the most effusive comments that you could possibly imagine. Kaila mentioned a very experienced physician who said, "Hey, I think that Bulkamid's going to take up 80% of the sling market even." We're seeing that kind of enthusiasm, a willingness of these urologists and urogynecologists to speak publicly about their experiences. We referenced previously that people should give a listen to the session that took place at SUFU, the conference, which we have a playback on our website. In that playback, you can hear from three physicians that are using Bulkamid that weren't even our customers. They weren't even Axonics customers previously. They had a very much of an unbiased view. Anyway, it's really going quite well. This is a product that really works and truly is easy to inject and is getting great results on these patients immediately. You can imagine, you go in for a set of injections, you do a bit of a cough test, and then they walk out dry. That's incredible. We're going to start to see a lot of goodwill being generated from patients in these practices. Those patients talking to other family members, friends, and so on and so forth about their experience, and having satisfied physicians who are helping make their patients better. That is the name of the game in the end of the day, right? The docs love the idea to get the instant gratification that they're doing something that's really helping a person, increasing their quality of life, and it happens immediately. There's no delayed reaction. They can see it right there before the patient leaves the practice. All in all, it's great. We just remind people that this is a product that sells for like $1,000 a patient, right? Compared to almost $16,000 for sacral neuromodulation. The meter doesn't move quite as fast when you're selling Bulkamid, right? A really good customer is going to do between 100,000 and 200,000 for us. That represents 100 to 200 patients, which is fantastic. The revenue, it just doesn't add up the way the sacral neuromodulation revenue adds up. Having said all that, it's great for our business. It's great for our position in the marketplace and for creating these long-lasting relationships with our customers. Okay, great. I mentioned Dan, so I have to get one in for him that actually is for him. Gross margins, this manufacturing issue that you called out, can you maybe just explain what that was? I have to ask the obligatory semiconductor supply question. Are you sure you're going to have adequate supply there given all the headlines we've seen about that? Thanks. It's a great question. As I said on the call, the decrease in the margin for the quarter is really just a result of manufacturing variances, which included more yield loss than we had planned. It's just as straightforward as that. As we produce more products and work through these inefficiencies, we'll see margin improvements, and our target is still to reach mid-70s at scale. There's no change in plan. If you look at the balance sheet, we increased the amount of inventory, and if you look at the amount of finished goods that we have in particular, we have plenty of product on the shelves to continue to meet demand for the foreseeable future. We are actually quite pleased, given the worldwide shortage on chips, capacitors, and resistors. I'd love to tell you that we were strategically brilliant, and we looked forward and saw this coming as a result of the pandemic. The truth of the matter is, look, we were preparing for rapid growth, which we've experienced, and it just so happens having significant inventory is going to be to our advantage given the shortages other people are experiencing. Okay, great. Thank you. Thank you. Your next question is from Adam Maeder with Piper Sandler. Hey, guys. Thanks for taking the questions here. Congrats on the nice start to the year. Thanks, Adam. Two from me. First one is on sacral market growth. I think you've talked, Ray, a little bit in the past about just a potential long tail of SNM accounts or implanters who have maybe been a bit underappreciated or overlooked historically. I'm wondering how much of the market growth that we're seeing today is from new or newer docs to the procedure, and how do you think about the contribution to growth from this group or this opportunity going forward? I had a follow-up. Okay, sure. Thanks, Adam. That's a good question. At the moment, I would tell you that we are definitely adding some of these customers from the long tail. All right? That's happening. They're primarily, up till now, physicians that are looking to just get back into the game in a bigger way, right? Particularly coming out of the pandemic, right? Everybody's practices have been down, and we got a better mousetrap and all that. They seem to be enthusiastic, and we'd like to get those dabblers, the people that are doing one a month. We've signed a number of them recently. If you can get them up to two or three per month, they're right in the fat part of the business for us. There's some of that. We've also learned because of the pandemic, we had to figure out, how could we do virtual training? Dr. Noblett, in particular, has spearheaded this initiative where we now have tools that we can actually train people virtually with pretty sophisticated tools and really bring them through best practices and so on and so forth. For the first time, and this was not part of our strategy in 2020, and I was very clear that in 2020, we only called on people that were doing sacral neuromodulation already. In 2021, we're now just starting to bring some physicians into the game who want to be doing sacral neuromodulation that have never done it before, because we're now in a position to be able to support that initiative. We've got the tools, we've got the people. We have a whole clinical education department now that we didn't have before, with five professionals in it led by Dr. Noblett. You're going to start to see some of that contributing to the growth and so forth. Adam, it's not one thing, as you could imagine. It's a number of all of these types of initiatives that we're doing conspiring together to help fuel the growth in the marketplace. Your next question comes from the line of Cecilia Furlong with Morgan Stanley. Hi, this is Marissa Bych on for Cecilia. I just wanted to go back to the primary cell device progress. We understand you plan to submit that to the FDA in the next month or so. Is there anything more specific you can tell us as far as launch plans for this in the first or second quarter of next year? Are you preparing to commercialize as soon as you have FDA approval, or are there any further steps on prototyping or trialing that we would need to see? Thank you very much. Sure. Thanks, Marissa. We're going to look to launch this product immediately after FDA approval. We are ramping up our manufacturing capabilities, if you may, to be able to produce the product ahead of the approval. We'll build product, I shouldn't say at risk because there's no risk, but we'll build product. We're revamping space in our manufacturing facility. This also, by the way, has a small part to play in kind of some of the comments that Dan has made and so forth. Things are a little bit in flux now as we get prepared to produce this new product. Nothing that would stand in our way per se. Our philosophy has been that we don't go to market with prototypes. We don't put prototypes in people's bodies. We're talking about a finished commercial product that I'd be comfortable to put in my mom. I may sound corny, but that's our philosophy. Having said that, will we run some type of post-market study so that we can provide additional comfort to the market? Yes, certainly we will. I think ARTISTRY is representative of our commitment to these types of things, and we'll obviously look to do some of that work as well with the non-rechargeable product. This will be a ready to rock and roll, full-blown commercial product that we'll look to ship as quickly following FDA approval as possible, which has been our custom, by the way. If you look at whether it's second generation or third generation devices that we've put out, we don't write off stuff. We haven't been writing off these previous models. We sell them out, we plan and prepare for the new version as it comes out. We feel really comfortable about this. I wish that we could put the product in the market today. This is the best we could do given COVID and everything else that has transpired till now. We'll take it in 2022 and we're excited about the impact that this product can make on the company and the market. Your next question will come from Danielle Antalffy with SVB Leerink. Hi, this is Rebecca Wang for Danielle. I want to circle back to Bulkamid. Can you update us on your headcount in sales reps and? Okay. Operator, we seem to have lost Rebecca. Danny? Danielle, please repeat your question. Oh, sorry. Yes. My first question is, can you update us on your headcount in sales reps and clinical specialists, including those reps you got from Bulkamid? Next question, I understand there are potential sales synergies, and you said your own sacral neuromodulation reps will contribute to Bulkamid sales in third quarter. Could you give us more color here? What is your strategy to deploy those sales reps and clinical specialists to drive things yourself without distractions to the core sacral neuromodulation business? Thank you so much. Okay. Rebecca, in my prepared remarks, I thought I had provided some very detailed numbers. I'll repeat it. In the U.S., we have 107 salespeople, including sales managers. We have nearly 110 clinical and therapy support specialists. We've got almost a half a dozen field marketing specialists and a clinical education group of five. If you run those numbers, it totals up pretty quickly. In Europe, we have 27 people that are selling either Bulkamid or sacral neuromodulation. That's how you get to the 250 number. All right. Thank you. Yeah. In terms of how do you introduce a new product in the marketplace without screwing up your existing business? I think that was your question. I think the only real answer is professional sales management and strong leadership and guidance from the people who run the business. You can't focus all your energy as a salesperson on a product that sells at $1,000 a patient versus one that could be around $16,000, right? The good news is that salespeople are, how should we say, their nature, their inherent nature is that they take the path of least resistance, and they go where the money is. That's why you hire professional salespeople to do this job. Let me just say that I am 100% confident in my Chief Commercial Officer, Al Ford, in our sales managers that are out there in the United States and internationally, that they are expert at this business, and they know how to manage people, and that we do not expect to see any drop-off or any cannibalization, let's say, of our energy. People understand that sacral neuromodulation is our core business. That's what keeps the lights on, so to speak. That's where they're heavily incentivized, of course, to spend their time. People get paid commission in our company based on volume. It's pretty straightforward, right? The more sacral neuromodulation you sell, the more money you're going to make. If Bulkamid can help you get into accounts that you're not in, and you can make some of your customers happy and all that with this product, then win-win-win all the way around for everybody. Thank you, speakers. Q&A session is now complete. I will now hand it back over to Raymond Cohen for the closing remarks. Thank you. Thank you, operator. Thank you to all the analysts who volunteered a question on today's call. Very helpful also for me to get the rest of the story out. We really appreciate your interest. To all shareholders, we appreciate your confidence in the company, and we look forward to talking with you again shortly. You all have a nice evening. This concludes today's conference call. Thank you for participating. You may now disconnect.